Evidence map›Paper›PMID 40803690›Full record

Trial reportExperimental dermatology2025

An Acid-Oxidising Solution Containing Hypochlorous Acid Reduces Staphylococcus aureus and Improves Bacterial Diversity in Epidermolysis Bullosa Wounds.

Xiaolong A Zhou, Michael B Burns, Ziyou Ren, Elise Stagaman, Stefan J Green, Lok Yiu Ashley Wu, Lynna Yang, Stephanie Rangel, Lydia Rabbaa, Amy S Paller

Abstract readClinical Trial
In one paragraph

Trial report in Experimental dermatology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Trial
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xiaolong A ZhouDepartment of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0002-6177-2472
Michael B BurnsDepartment of Biology, Loyola University Chicago, Chicago, Illinois, USA.
Ziyou RenDepartment of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-7127-4197
Elise StagamanDepartment of Biology, Loyola University Chicago, Chicago, Illinois, USA.
Stefan J GreenGenomics and Microbiome Core Facility, Rush University Medical Center, Chicago, Illinois, USA.
Lok Yiu Ashley WuGenomics and Microbiome Core Facility, Rush University Medical Center, Chicago, Illinois, USA.
Lynna YangDepartment of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Stephanie RangelDepartment of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Lydia RabbaaDepartment of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.
Amy S PallerDepartment of Dermatology, Northwestern University, Feinberg School of Medicine, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-6187-6549

Funding

Applied Pharma Research
6 · The paper itself

Abstract

Epidermolysis bullosa (EB) is a group of rare genetic skin disorders characterised by skin fragility and chronic, painful wounds that are highly susceptible to bacterial infection, particularly by Staphylococcus aureus (SA). This study evaluated the efficacy of an acid-oxidising solution containing hypochlorous acid (HOCl) in reducing SA colonisation, promoting wound healing, and restoring a healthier microbiome in EB wounds. In a 12-week open-label pilot study, 15 EB patients applied the HOCl-based spray (APR-TD011) daily to chronic wounds for 8 weeks, with full-length 16S rRNA sequencing of wound swabs performed before, during, and after treatment. At baseline, 87% of patients were culture-positive for SA, and sequencing revealed that SA had the highest relative abundance (34%), followed by Acinetobacter guillouiae and Pseudomonas poae. SA relative abundance decreased precipitously by Weeks 4 (to 11%) and 8 (primary endpoint; to 10%, p < 0.01), and this effect persisted at 4 weeks post-treatment (Week 12; to 9.7%), including for methicillin-resistant SA. Concurrently, bacterial diversity increased, and wound sizes diminished in correlation with reduced SA levels (r = 0.64). Younger patients exhibited greater SA reduction trends. The treatment was well-tolerated, with minimal adverse effects and high patient satisfaction. This study underscores the role of microbial dysbiosis in EB wounds and highlights HOCl-based solutions as a promising therapy to mitigate pathogenic burden and enhance wound healing.

Indexed as

DysbiosisEpidermolysis BullosaHypochlorous AcidSkin MicrobiomeStaphylococcal Skin InfectionsAdministration, CutaneousAdolescentAdultChildChild, PreschoolFemaleHumansInfantMaleMiddle AgedPilot ProjectsHypochlorous Acidacid‐oxidising solutionepidermolysis bullosahypochlorous acidmicrobiomeStaphylococcus aureuswounds

Identifiers

PMID40803690
PMCPMC12349993

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.